Li Tongjun, Lin Shaoling, Zhu Yingyin, Ye Dewei, Rong Xianglu, Wang Lexun
Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China; Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine; Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Cell Death Discov. 2025 Mar 14;11(1):102. doi: 10.1038/s41420-025-02357-4.
CCAAT/enhancer-binding protein delta (CEBPD), as an evolutionarily conserved protein in mammals, belongs to the CEBP transcription factor family, which modulates many biological processes. The diversity of CEBPD functions partly depends on the cell type and cellular context. Aberrant CEBPD expression and activity are associated with multiple organ diseases, including cardiovascular diseases. In this review, we describe the basic molecular biology of CEBPD to understand its expression regulation, modifications, and functions. Here, we summarize the recent advances in genetically modified animals with CEBPD. Finally, we discuss the contribution of CEBPD to cardiovascular diseases and highlight the strategies for developing novel therapies targeting CEBPD.
CCAAT/增强子结合蛋白δ(CEBPD)作为哺乳动物中一种进化保守的蛋白质,属于CEBP转录因子家族,该家族调节许多生物学过程。CEBPD功能的多样性部分取决于细胞类型和细胞环境。CEBPD的异常表达和活性与包括心血管疾病在内的多种器官疾病相关。在本综述中,我们描述CEBPD的基本分子生物学,以了解其表达调控、修饰和功能。在此,我们总结了CEBPD基因编辑动物的最新研究进展。最后,我们讨论了CEBPD对心血管疾病的作用,并强调了开发针对CEBPD的新型治疗策略。